Treatment failure in around 10% of about 300 patients was associated with large cysts / pseudocysts, non-compliance in unreformed alcoholics, undiagnosed neoplasia in two (adenocarcinoma, papillary mucinous) and in the described patients with recurrent acute pancreatitis (JM Braganza, unpublished)
The platform's published materials describe a range of possible side effects patients may experience: Commonly reported mild effects include nausea, constipation, bloating, burping, mild headache, and fatigue effects that the patient protocols describe as typically improving as the body adjusts to the medication
In 2023, the FDA added a warning about ileus blockage of the intestines showing that these side effects are a serious concern
GLP-1 RA exenatide alleviated the polycystic ovarian morphology in rats with PCOS, semaglutide treatment not only alleviated PCOS phenotypes but also reversed ovarian ferroptosis markers, restored GPX4 expression, and reduced the GPX4 promoter hypermethylation and DNMTs levels, with efficacy comparable to 5-azacytidine